CD274 and hepatocellular carcinoma: The combination therapy of PD-L1 inhibitors and anti-angiogenic drugs, especially the regimen of atezolizumab combined with bevacizumab, has been recommended as the preferred treatment option for patients with advanced HCC by major clinical guidelines [11].